Palisade Bio, Inc. Share Price
PALIPalisade Bio, Inc. Stock Performance
Open $1.73 | Prev. Close $1.74 | Circuit Range N/A |
Day Range $1.64 - $1.76 | Year Range $0.53 - $2.85 | Volume 1,45,384 |
Average Traded $1.69 |
Palisade Bio, Inc. Share Price Chart
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Palisade Bio, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
09-Jun-26 | $1.73 | $1.69 | +0.00% |
09-Jun-26 | $1.73 | $1.69 | -2.59% |
08-Jun-26 | $1.75 | $1.74 | +0.00% |
05-Jun-26 | $1.93 | $1.74 | -10.10% |
04-Jun-26 | $1.92 | $1.93 | +0.00% |
03-Jun-26 | $1.84 | $1.93 | +4.04% |
02-Jun-26 | $2.05 | $1.85 | -11.67% |